Omitting axillary surgery in breast cancer treated with neoadjuvant chemotherapy

Axillary surgery has traditionally been used to control axillary metastasis and provide staging for further treatment planning. However, landmark trials like the ACOSOG Z0011 have demonstrated that axillary treatment does not offer a survival benefit, leading to a significant shift towards less aggressive management in early breast cancer (1). As a result, surgical approach has shifted from extensive axillary lymph node dissection (ALND) to the standardization of the less invasive sentinel lymph node biopsy (SLNB). Building on these trends, prospective trials are now exploring the possibility of omitting axillary surgery altogether in patients with clinically and radiologically node-negative early breast cancer.

The SOUND trial by Gentilini et al. was among the first to demonstrate that omitting axillary surgery is noninferior to SLNB in patients with small breast cancers (up to 2 cm) and negative axillary lymph node on ultrasonography (USG) (2). The success of such trials depends on accurate assessment of nodal burden to avoid clinical recurrences due to undetected disease. In the SOUND trial, the false-negative rate (FNR) for USG-determined nodal status was 13.7%. Currently, trials are ongoing for patients with larger tumors (up to 5 cm), including the NAUTILUS, INSEMA, BOOG 2013-08, and SOAPET trials (3).

Attention has now turned to de-escalating or omitting axillary surgery in patients who have received neoadjuvant chemotherapy (NCT). The ICARO study retrospectively examined the omission of ALND in patients with isolated tumor cells after NCT and found no significant difference in any invasive recurrence rates between those who underwent ALND and those who did not (4). Prospective trials, such as Alliance A001102, TAXIS, and ADARNAT were designed earlier to investigate if axillary radiotherapy could replace ALND in patients who have positive sentinel lymph nodes following NCT (5-7). Additionally, a retrospective analysis study using the National Cancer Database of 30,821 NCT patients with cT1–2, cN0–1 breast cancer found that nodal positivity was less than 2% in human epidermal growth factor receptor 2-positive (HER2⁺) or triple-negative breast cancer (TNBC) when there was no residual tumor in the breast following a good response to NCT (8). Consequently, three prospective trials (ASLAN, ASICS, EUBREAST-01) are investigating the safety of omitting axillary surgery in patients with a pathologic complete response in the breast.

Despite these trends, concerns remain about omitting axillary surgery, primarily due to the potential for missing metastatic lymph nodes and losing crucial nodal information needed for treatment planning. False negatives could result in patients not receiving necessary adjuvant systemic therapy or radiotherapy.

A recent study by Zaborowski et al. provides real-world insights into lymph node positivity rates after NCT (9). This multicenter, retrospective study assessed post-NCT nodal status in 371 patients with clinically and radiologically node-negative breast cancer, all with negative post-NCT axillary lymph node on USG. The overall nodal positivity was 12.7%, with the highest rates in hormone receptor (HR)⁺/HER2⁻ breast cancer (29.0%), followed by HR⁺/HER2⁺ (13.8%), TNBC (6.5%), and HR⁻/HER2⁺ (5.6%). These results are similar to those reported by Barron et al. in cT1–2, cN0 patients (8).

When planning future trials on omitting axillary surgery post-NCT, it is crucial to consider acceptable FNRs. The SOUND trial had an USG FNR of 13.7%, while the FNR for SLNB itself was 9.8% in the NSABP B-32 trial (10). For patients converting from clinical node-positive (cN+) to clinical node-negative (ycN0) status, SLNB FNRs were reported to exceed 10% in most of studies: 14.2% in SENTINA, 12.6% in ACOSOG Z1071, and 13.3% in SN FNAC (11-13). Future trials for omitting axillary surgery in post-NCT patients might include TNBC and HER2⁺ patients meeting the criteria from Zaborowski et al., and consider HR⁺/HER2⁻ patients with a good breast response to NCT.

The inclusion criteria for cN0 in Zaborowski et al.’s study were very strict, utilizing both USG and positron emission tomography (PET)/computed tomography (CT) for axillary staging. While routine PET/CT could improve the accuracy of predicting negative axillary lymph node status, it may reduce the study’s generalizability. Magnetic resonance imaging is currently recommended for use in patients who have received NCT, and its role in lymph node evaluation should be considered in future studies.

Overall, the findings from Zaborowski et al. offer valuable evidence on nodal status in cT1–3, cN0 breast cancer post-NCT, supporting the design and refinement of further trials on de-escalating axillary surgery in selected patients.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Gland Surgery. The article has undergone external peer review.

Peer Review File: Available at https://gs.amegroups.com/article/view/10.21037/gs-24-210/prf

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-24-210/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Turnbull AR, Turner DT, Chant AD, et al. Treatment of early breast cancer. Lancet 1978;2:7-9.
2. Gentilini OD, Botteri E, Sangalli C, et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol 2023;9:1557-64.
3. Hersh EH, King TA. De-escalating axillary surgery in early-stage breast cancer. Breast 2022;62:S43-9.
4. Montagna G, Laws A, Ferrucci M, et al. Abstract GS02-02: Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study. Cancer Res 2024;84:GS02-02.
5. Caudle AS, Kuerer HM. Targeting and limiting surgery for patients with node-positive breast cancer. BMC Med 2015;13:149.
6. Maggi N, Nussbaumer R, Holzer L, et al. Axillary surgery in node-positive breast cancer. Breast 2022;62:S50-3.
7. Garcia-Tejedor A, Ortega-Exposito C, Salinas S, et al. Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial). Front Oncol 2023;13:1184021.
8. Barron AU, Hoskin TL, Day CN, et al. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. JAMA Surg 2018;153:1120-6.
9. Zaborowski AM, Doogan K, Clifford S, et al. Nodal positivity in patients with clinically and radiologically node-negative breast cancer treated with neoadjuvant chemotherapy: multicentre collaborative study. Br J Surg 2024;111:znad401.
10. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-33.
11. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310:1455-61.
12. Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015;33:258-64.
13. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013;14:609-18.